Literature DB >> 18066816

2'-O-hydroxyalkoxymethylribonucleosides and their incorporation into oligoribonucleotides.

Sergey N Mikhailov1, Georgii V Bobkov, Kyrill V Brilliantov, Jef Rozenski, Arthur Van Aerschot, Piet Herdewijn, Michael H Fisher, Rudolph L Juliano.   

Abstract

A simple and efficient method for the preparation of pyrimidine 2'-O-hydroxyethoxymethylribonucleosides and 2'-O-hydroxypropoxymethylribonucleosides has been developed. These modified nucleosides were incorporated into oligoribonucleotides, which were shown to form stable RNA/RNA duplexes. The effect of 2' -O-modification in the antisense and sense strands of small interference RNA was evaluated in multi-drug resistant NIH 3T3 cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18066816      PMCID: PMC2692904          DOI: 10.1080/15257770701543007

Source DB:  PubMed          Journal:  Nucleosides Nucleotides Nucleic Acids        ISSN: 1525-7770            Impact factor:   1.381


  7 in total

Review 1.  Ribozymes, DNAzymes and small interfering RNAs as therapeutics.

Authors:  Mouldy Sioud; Per Ole Iversen
Journal:  Curr Drug Targets       Date:  2005-09       Impact factor: 3.465

2.  Synthesis of amine- and thiol-modified nucleoside phosphoramidites for site-specific introduction of biophysical probes into RNA.

Authors:  Shengxi Jin; Chandrasekhar V Miduturu; David C McKinney; Scott K Silverman
Journal:  J Org Chem       Date:  2005-05-27       Impact factor: 4.354

Review 3.  2'-carbohydrate modifications in antisense oligonucleotide therapy: importance of conformation, configuration and conjugation.

Authors:  M Manoharan
Journal:  Biochim Biophys Acta       Date:  1999-12-10

4.  The ups and downs of nucleic acid duplex stability: structure-stability studies on chemically-modified DNA:RNA duplexes.

Authors:  S M Freier; K H Altmann
Journal:  Nucleic Acids Res       Date:  1997-11-15       Impact factor: 16.971

Review 5.  Oligonucleotides as anticancer agents: from the benchside to the clinic and beyond.

Authors:  Francesca Marietta Coppelli; Jennifer Rubin Grandis
Journal:  Curr Pharm Des       Date:  2005       Impact factor: 3.116

6.  Strategies for inhibition of MDR1 gene expression.

Authors:  Dong Xu; Hyunmin Kang; Michael Fisher; R L Juliano
Journal:  Mol Pharmacol       Date:  2004-08       Impact factor: 4.436

Review 7.  Antisense technologies. Improvement through novel chemical modifications.

Authors:  Jens Kurreck
Journal:  Eur J Biochem       Date:  2003-04
  7 in total
  1 in total

Review 1.  Biological barriers to therapy with antisense and siRNA oligonucleotides.

Authors:  R Juliano; J Bauman; H Kang; X Ming
Journal:  Mol Pharm       Date:  2009 May-Jun       Impact factor: 4.939

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.